RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated September 13, 2006, titled "Ranbaxy Invalidates Pfizers 281 Patent in the Netherlands". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated September 12, 2006, titled "Ranbaxy Launches Avessa for the treatment of Asthma - World's First Novel Product Introduced in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 11,2006, titled "Ranbaxy receives USFDA approval to market Loperamide Hydrochloride and Simethicone Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 30,2006, titled "Ranbaxy wins on two additional Atorvastatin Patents in Norway - Three of four patent rulings now favour Ranbaxy". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that Zenotech Laboratories Ltd., Hyderabad has made a Preferential Allotment of 20,00,000 Equity Shares of Rs.10 each at a premium of Rs.90 per share to Ranbaxy Laboratories Ltd. on August 25, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 18, 2006, titled "Ranbaxy Launches Soliten for Treatment of Urology Disorder Product Introduced for the First Time in India". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that following the recent acquisition of Terapia in Romania, there are significant operational effeciences to be gained from consolidating the Company's European manufacturing operations in Romania. This is consitent with the Company's strategy to make Romania the strategic hub for markets in Europe and the Commonwealth of Independent States (CIS). Consequently, Ranbaxy has decided to divest the manufacturing facility of Ranbaxy Ireland Ltd. located in Cashel, Ireland, as a going concern.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 04,2006, titled "Ranbaxy receives tentative approval from US FDA to market Risperidone Oral Solution". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 03,2006, titled "Ranbaxy Invalidates Pfizer's '995 Lipitor U.S. Patent - CAFC overturns earlier District Court ruling on the same patent". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 02,2006, titled "Ranbaxy's US subsidiary Ohm Labs receives Prestigious Private Label Supplier of the Year award from AmerisourceBergen". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has submitted to the Exchange a copy of minutes of the AGM of the Company held on June 28,2006. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated July 20, 2006, titled "Ranbaxy Q2 Global Sales at Rs. 14,464 MN, Records 7% Growth - Net Profit At Rs. 1,211 MN, Record 20% Growth- Ebidta Margins at 18.3% Records Growth of 56%". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 19, 2006, titled "Ranbaxy signs licensing and supply agreement for the Canadian market First Indian Company to market a licensed generic in Canada". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 18, 2006, titled "Ranbaxy to acquire the Mundogen Generic Business of Glaxosmithkline in Spain". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboraetories Ltd has informed the Exchange regarding a press release dated July 17,2006, titled "Ranbaxy's Joint Venture in Japan launches Generic Clarithromycin & Terbinafine Tablets". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs Allotment Committee of Directors at its meeting held on July 12,2006 has allotted 62,548 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Shares Capital of the Company post allotment is 372654164 Equity Shares of Rs.5 each aggregating Rs.1863270820.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated June 30, 2006, titled "Ranbaxy Receives US FDA Approval to Market Cefprozil Suspension". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 28,2006, titled "U.K. Appeals Court Affirms Mixed High Court of Justice's Ruling in Lipitor� Case". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 23, 2006, titled "Ranbaxy Receives USFDA Approval To Market 80MG Simvastatin Tablets with 180-Day Exclusivity - Cholesterol - Lowering Simvastatin Currently Marketed in the U.S. as Zocor �". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

News Verification : The media had reports that Ranbaxy Laboratories Ltd is likely to pick up stake in a mid-sized Indian drug company for Rs. 20 crores. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated,"As a part of our overall business strategy, we do evaluate various growth opportunities (including possible alliances, investments and acquisition opport

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 09, 2006, titled "Ranbaxy to Market Zonisamide Capsules in the US" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 08, 2006, titled "Ranbaxy achieves closure on Terapia deal as Romanian Competition Council approves acquisition". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 07, 2006, titled "Ranbaxy Inc. Announces a Strategic Partnership with Zenotech for Oncology Products". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, June 02, 2006, titled "Ranbaxy receives approval from US FDA to market Doxycycline Tablets" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, May 24, 2006, titled, "Ranbaxy in-licences NDDS analgesic molecule from Ethypharm-France, for India - Adds muscle to its strategic portfolio of Novel drugs".The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a Press Release dated May 24,2006, titled "Ranbaxy gains WHO pre-qualification for four more ARVs". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, May 17, 2006, titled "Ranbaxy in-licences new Asthma drug from European Laboratories, Netherlands - Product to be marketed in India for the first time". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, April 25, 2006, titled, "Ranbaxy Sucessfully Invalidates Atorvastatin Patent in Austria". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)

News Verification : The media had reports that Ranbaxy Laboratories Ltd is likely to hive off its research and development (R&D) division into a separate company.. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Ranbaxy Laboratories Ltd has vide its letter inter-alia stated, "The aforesaid news item does not reflect the true simulation. Our R&D is a core inhouse activity of the company. In the case of special proje

Ranbaxy Laboratories Ltd has informed the Exchange that an interim Dividend of Rs.2.50 per share was paid in November, 2005. Board has now recommended a final dividend of Rs.6 (Rupees six) per share for the year ended December 31, 2005 taking the total dividend for the year to Rs.8.50 per share of par value of Rs.5 each (2004-total dividend Rs.17 per share of par value of Rs.10 each).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, April 19, 2006, titled, "Ranbaxy Q1, 06, Global Sales at USD 287 Mn, up 14 per cent - Board recommends final dividend of Rs. 6 per share" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that Share transfer books for the purpose of determination of entitlement of final dividend will remain closed from June 17, 2006 to June 28, 2006 (both days inclusive). Further, Annual General Meeting has been fixed for June 28, 2006.

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. Shivinder Mohan Singh, Director of the company has sold 303306 shares on April 4, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr shivinder Mohan Singh after the said sale is 2120742 shares aggregating 0.57% of the total share capital of Ranbaxy Laboratories Ltd..

Ranbaxy Laboratories Ltd has informed the Exchange that (1) Mr Malvinder Mohan Singh has acquired 439032 shares on April 03, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr Malvinder Mohan Singh after the said acquisition is 2877342 shares aggregating to 0.77% of the total share capital of Ranbaxy Laborities Ltd.. (2) Mr. Malvinder Mohan Singh, Chief Executive Officer and Managing Director of the company has sold 302908 shares on April 4, 2006 of Ranbaxy Laboratories Ltd. The shareholding of Mr Malvinder Mohan Singh after the said sale is 2574434 shares aggregating 0.69% of the total

Ranbaxy Laboratories Ltd has informed the Exchange that the ESOPs allotment Committee of Directors at its meeting held on April 10, 2006 has allotted 117,423 Equity Shares on exercise of stock options under the Employees Stock Option Scheme(s) of the Company. The paid-up Equity Shares Capital of the Company post allotment is 372591616 Equity shares of Rs.5 each aggregating Rs.1862958080.

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press statement dated April 05, 2006 titled "RANBAXY (UK) LTD - C.P.House, 3rd Floor, 97-107 UXBRIDGE ROAD, EALING, LONDON W5 5TL". The details of the press statement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 30, 2006, titled, "RANBAXY ACQUIRES ETHIMED IN BELGIUM - Offers Ranbaxy strategic market access and distribution network for Benelux countries". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 29, 2006, titled, "Ranbaxy Acquires Leading Romanian Pharma company Terapia for US $324m - Major Strategic Step in expanding European operations - New entity will be the largest generic company in Romania". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 27, 2006, titled, "Ranbaxy to Acquire the Unbranded Generic Business of Glaxosmithkline in Italy." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, March 24, 2006, titled, "Ranbaxy Launches Osonide Inhaler for the treatment of Asthma; Novel product introduced for the First time in India." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has issued US$ 440,000,000 Zero Coupon Convertible Bonds due 2011 (including US$ 40,000,000 in aggregate principal amount of Bonds issued pursuant to an overallotment option granted by the Company to the Lead Managers, which has been exercised in whole).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, March 21, 2006, titled, "RANBAXY PURCHASES RIGHTS AND ASSETS TO SENETEK'S AUTOINJECTOR DEVICE', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated, March 09, 2006, titled, "Ranbaxy enters into a strategic alliance with Zenotech - Agreement heralds Ranbaxy's entry into the Oncology segment in LATAM, Russia & other CIS markets', being issued by the Company. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Fidelity International has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has sold 759,770 shares aggregating to 0.20% of the total paid up capital of Ranbaxy Laboratories Ltd on February 23, 2006. The mode of sale is Open market and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said sale is 17,988,673 shares aggregating t

Ranbaxy Laboratories Ltd has informed the Exchange that Mr. V.K. Kaul, Director has sold 52,000 shares of Ranbaxy Laboratories Ltd on February 21, 2006. The mode of sale is Market sale and the shareholding of Mr. V.K. Kaul after the said sale is 200 shares of Ranbaxy Laboratories Ltd.

Ranbaxy Laboratories Ltd has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has sold 759,770 shares aggregating to 0.20% of the share capital of Ranbaxy Laboratories Ltd on February 23, 2006. The mode of sale is market sale and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said sale is 17,988,673 shares aggregating to 4.83

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated, February 16, 2006, titled, "Ranbaxy Laboratories Limited places US$ 400 million Foreign Currency Convertible Bonds; Single largest capital raising by an Indian healthcare company." The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).

Ranbaxy Laboratories Ltd has informed the Exchange that the Company has clarified that there have been several recent press reports speculating about potential acquisitions that may be made by the Company. The Company has previously stated that part of its strategy is to grow through acquisitions. From time to time the Company may consider a range of acquisitions and may make bids in competitive tenders. The details of the press release issued by the company on February 15, 2006 in this regard shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announceme

Ranbaxy Laboratories Ltd has informed the Exchange that the Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 258,626 shares aggregating to 0.07% of the total paid up capital of Ranbaxy Laboratories Ltd on February 01, 2006. The mode of acquisition is through Market purchase and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisitio

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release, dated February 06, 2006, titled "Ranbaxy Forms Joint Venture in South Africa to Supply ARV Medicines for Africa Market". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).